主题：【已应助】求助五篇文章

【序号】：1
【作者】：Haghighat S
【题名】：Recombinant PBP2a as avaccine candidate against methicillin-resistant Staphylococcus aureus:Immunogenicity and protectivity.
【期刊】：Microb Pathog.
【年、卷、期、起止页码】：2017 Jul;108:32-39.
【全文链接】：https://www.ncbi.nlm.nih.gov/pubmed/28457901
【序号】：2
【作者】：Haghighat S
【题名】：Cloning, expression andpurification of autolysin from methicillin-resistant Staphylococcus aureus:potency and challenge study in Balb/c mice.
【期刊】：Mol Immunol.
【年、卷、期、起止页码】：2017 Feb;82:10-18.
【全文链接】：https://www.ncbi.nlm.nih.gov/pubmed/28006655
【序号】：3
【作者】：Begier E
【题名】：SA4Ag, a 4-antigenStaphylococcus aureus vaccine, rapidly induces high levels of bacteria-killingantibodies.
【期刊】：Vaccine.
【年、卷、期、起止页码】：2017 Feb 22;35(8):1132-1139.
【全文链接】：https://www.ncbi.nlm.nih.gov/pubmed/28143674
【序号】：4
【作者】：Creech CB
【题名】： Safety,tolerability, and immunogenicity of a single dose 4-antigen or 3-antigenStaphylococcus aureus vaccine in healthy older adults: Results of a randomisedtrial.
【期刊】：Vaccine.
【年、卷、期、起止页码】： 2017 Jan 5;35(2):385-394.
【全文链接】：https://www.ncbi.nlm.nih.gov/pubmed/27866765
【序号】：5
【作者】：Frenck RW Jr
【题名】： Safety,tolerability, and immunogenicity of a 4-antigen Staphylococcus aureus vaccine(SA4Ag): Results from a first-in-human randomised, placebo-controlled phase 1/2study.
【期刊】：Vaccine.
【年、卷、期、起止页码】：  2017 Jan 5;35(2):375-384.
【全文链接】：https://www.ncbi.nlm.nih.gov/pubmed/27916408